Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or...
Reexamination Certificate
2003-12-15
2009-06-23
Helms, Larry R. (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
C435S007230, C435S070100, C436S064000
Reexamination Certificate
active
07550256
ABSTRACT:
Disclosed are methods for detecting multidrug resistance in neoplastic or damaged cells or multidrug resistant (MDR) neoplastic or damaged cells by detecting an increase in the cell surface expression of vimentin protein in such cells as compared to the level of cell surface expression of vimentin protein in a normal cell or a non-MDR neoplastic cell.
REFERENCES:
patent: 4444744 (1984-04-01), Goldenberg
patent: 4720386 (1988-01-01), McCollester
patent: 5194384 (1993-03-01), Bystryn
patent: 5407653 (1995-04-01), Piwnica-Worms
patent: 5762930 (1998-06-01), Fanger et al.
patent: 5801154 (1998-09-01), Frank et al.
patent: 6338853 (2002-01-01), Bystryn
patent: 6352996 (2002-03-01), Cao et al.
patent: 6406689 (2002-06-01), Falkenberg et al.
patent: 6417336 (2002-07-01), Morishima et al.
patent: 6476193 (2002-11-01), Nandabalan et al.
patent: 6511676 (2003-01-01), Boulikas
patent: 6562347 (2003-05-01), Kwak et al.
patent: 6572856 (2003-06-01), Taylor et al.
patent: 6593087 (2003-07-01), Prichard et al.
patent: 6623923 (2003-09-01), Xu et al.
patent: 6630327 (2003-10-01), Mechetner et al.
patent: 6657048 (2003-12-01), Young et al.
patent: 2002/0061316 (2002-05-01), Srivastava
patent: 2002/0110912 (2002-08-01), Jatinder et al.
patent: 2002/0198139 (2002-12-01), Deutschman et al.
patent: 2003/0012793 (2003-01-01), Srivastava et al.
patent: 2003/0012794 (2003-01-01), Srivastava et al.
patent: 2003/0031661 (2003-02-01), Graner et al.
patent: 2003/0087412 (2003-05-01), Nandabalan et al.
patent: 2003/0157081 (2003-08-01), Bonini et al.
patent: 2003/0165519 (2003-09-01), Srivastava
patent: 2003/0180721 (2003-09-01), Witkin
patent: 2004/0185511 (2004-09-01), Georges et al.
patent: 0813872 (1997-12-01), None
patent: WO 02/071061 (2002-09-01), None
patent: WO 03/008542 (2003-01-01), None
S. Meschini1, A. Calcabrini1, E. Monti2, et al., Intracellular P-Glycoprotein Expression is Associated With the Intrinsic Multidrug Resistance Phenotype in Human Colon Adenocarcinoma Cells Int. J. Cancer: 87, 615-628 (2000).
A K. Heidenthal, PC. Weber, FLottspeich, and N Hrboticky, The Binding in Vitro of Modified LDL to the Intermediate Filament Protein Vimentin. Biochemical and Biophysical Research Communications 267, 49-53 (2000).
P.Thomas, D. Kirschmann, J Cerhan, Robert Folbert, E. Seftor, T. Sellers, andM. Hendrix, Association between Keratin and Vimentin Expression, Malignant Phenotype, and Survival in Postmenopausal Breast Cancer Patients. vol. 5, 2698-2703, Oct. 1999.
Essa et al., Vimentin expression i different types of breast carcinom aimmunohistochemical study J Egypt Soc Parasitol, vol. 26, pp. 433-442, 10996.
Bichart et al., Cytoskeletion alteration in MCF7R cells, a multifrug resistant human brast cancer cell line. Anticancer Res. vol. 17, pp. 3393-3401, 1997.
Freshney, Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p. 4.
Dermer , Bio/Technology, 1994, vol. 12, p. 320.
Kuszyk et al., American Roentgen Ray, vol. 177:747-753, 2001.
U.S. Appl. No. 10/801,988, filed Mar. 15, 2004, Geroges et al.
U.S. Appl. No. 10/736,889, filed Dec. 15, 2003, Georges et al.
Abou-Jawde et al., An Overview of Targeted Treatments in Cancer, Clinical Therapeutics, vol. 25, No. 8, 2003, pp. 2121-2137.
Alqawi and Georges, The multidrug resistance protein ABCC1 drug-binding domains show selective sensitivity to mild detergents, Biochemical and Biophysical Research Communications 303, 2003, pp. 1135-1141.
Barreto et al., Stress-induced release of HSC70 from human tumors, Cellular Immunology 222, 2003, pp. 97-104.
Cheng et al., Retaining of the Assembly Capability of Vimentin Phosphorylated by Mitogen-Activated Protein Kinase-Activated Protein Kinase-2, Journal of Cellular Biochemistry, 89, 2003, pp. 589-602.
Den Boer et al., Relationship Between Major Vault Protein/Lung Resistance Protein, Multidrug Resistance-Associated Protein, P-Glycoprotein Expression, and Drug Resistance in Childhood Leukemia, Blood, vol. 91, No. 6, 1998, pp. 2092-2098.
Di Pietro et al., Modulation by flavonoids of cell multidrug resistance mediated by P-glycoprotein and related ABC transporters, Cell. Mol. Life Sci. 59, 2002, pp. 307-322.
Du et al., Dual Requirement for Rho and Protein Kinase C in Direct Activation of Phospholipase D1 Through G Protein-coupled Receptor Signaling, Molecular Biology of the Cell, vol. 11, 2000, pp. 4359-4368.
Durbin et al., An epitope on carcinoembryonic antigen defined by the clinically relevant antibody PR1A3, Proc. Natl. Acad. Sci. USA, vol. 91, 1994, pp. 4313-4317.
Faigle et al., Vimentin Filaments in Fibroblasts Are a Reservoir for SNAP23, a Component of the Membrane Fusion Machinery, Molecular Biology of the Cell, vol. 11, 2000, pp. 3485-3494.
Feig, Designer Drugs: New Directed Therapies for Cancer, International Journal of Hematology Suppl. II, 76, 2002, pp. 281-283.
Fujita et al., High Molecular Weight Vimentin Complex Is Formed after Proteolytic Digestion of Vimentin by Caspase-3: Detection by Sera of Patients with Interstitial Pneumonia, Microbiol. Immunol., 47(6), 2003, pp. 447-451.
Garnett, Targeted drug conjugates: principles and progress, Advanced Drug Delivery Reviews, 53, 2001, pp. 171-216.
Goto et al., Phosphorylation and reorganization of vimentin by p21-activated kinase (PAK), Genes to Cells, 7, 2002, pp. 91-97.
Gratama et al., Flow Cytometric Quantitation of Immunofluorescence Intensity: Problems and Perspectives, Cytometry 33, 1998, pp. 166-178.
Heidenthal et al., The Binding in Vitro of Modified LDL to the Intermediate Filament Protein Vimentin, Biochemical and Biophysical Research Communications, 267, 2000, pp. 49-53.
Herrmann and AEBI, Intermediate filaments and their associates: multi-talented structural elements specifying cytoarchitecture and cytodynamics, Current Opinion in Cell Biology, 12, 2000, pp. 79-90.
Hubert et al., STEAP: A prostate-specific cell-surface antigen highly expressed in human prostate tumors, PNAS, vol. 96, No. 25, 1999, pp. 14523-14528.
Iqbal and Lenz, Targeted Therapy and Pharmacogenomic Programs, Cancer Supplement, vol. 97, No. 8, 2003, pp. 2076-2082.
Kim et al., Multidrug Resistance-Associated Protein (MRP) is expressed in osteosarcoma but is not a significant me(c)hanism of drug resistance, 47th Ann. Mtg., Orthopaedic Research Society, 2001, p. 0855.
Kim, Targeted therapies for the treatment of cancer, The American Journal of Surgery, 186, 2003, pp. 264-268.
Kown et al., In Vivo Imaging of Acute Cardiac Rejection in Human Patients Using 99m Technetium Labeled Annexin V, American Journal of Transplantation, 1, 2001, pp. 270-277.
Kreitman and Pastan, Immunotoxins for targeted cancer therapy, Advanced Drug Delivery Reviews, 31, 1998, pp. 53-88.
Ling, Multidrup resitance: molecular mechanism and clinical relevance, Cancer Chemother. Pharmacol., 40 Suppl., 1997, pp. S3-S8.
Meschini et al., Intracellular P-glycoprotein expression is associated with the intrinsic multidrug resistance phenotype in human colon adenocarcinoma cells, Int. J. Cancer, 87, 2000, pp. 615-628.
Mor-Vaknin et al., Vimentin is secreted by activated macrophages, Nature Cell Biology, vol. 5, 2003, pp. 59-63.
Park, Tumor-directed Targeting of Liposomes, Bioscience Reports., vol. 22, No. 2, 2002, pp. 267-281.
Patterson et al., Reduced Numatrin/B23/Nucleophosmin Labeling in Apoptotic Jurkat T-lymphoblasts, The Journal of Biological Chemistry, vol. 270, No. 16, 1995, pp. 9429-9436.
Rots et al., Targeted cancer gene therapy: the flexibility of adenoviral gene therapy vectors, Journal of Controlled Release, 87, 2003, pp. 159-165.
Rowlinson-Busza and Epenetos, Targeted delivery of biologic and other antineoplastic agents, Current Opinion in Oncology, 4, 1992, 1142-1148.
Schroeijers et al., the Mr 193,000 Vault Protein Is Up-Regulated in Multidrug-resistant Cancer Cell Lines, Cancer Research, 60, 2000, pp. 1104-1110.
Wehner et al., Expression levels of hsc70 and hsp60 are developmentally regulated during B-cell maturation and not associated to childhood c-All at presentation or relapse, Eur. J. Haematol., 71, 2003, pp. 100-108.
Steinert et al., A High Molecular Weight Int
Bonneau Anne-Marie
Dallaire Frédéric
Georges Elias
Serfass Lucile
Aurelium Biopharma, Inc.
Helms Larry R.
Wilmer Cutler Pickering Hale & Dorr LLP
Yao Lei
LandOfFree
Vimentin directed diagnostics and therapeutics for multidrug... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vimentin directed diagnostics and therapeutics for multidrug..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vimentin directed diagnostics and therapeutics for multidrug... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4122231